Country for PR: United States
Contributor: PR Newswire New York
Thursday, January 14 2021 - 18:00
Cytiva delivers modular biologics factory to Lonza
AMERSHAM, United Kingdom, Jan. 14, 2021 /PRNewswire-AsiaNet/ --

    - From site selection in Guangzhou Biopark to handover during the global 
      pandemic, 17,000-square meter site was completed in less than two years 
    - From Lonza's first manufacturing site for biologics in China, the 
      healthcare leader will provide services and manufacturing needed to 
      respond to growing global pharmaceutical needs 
    - Site to become a strategic base in China for Lonza to provide CDMO 
      services throughout Asia Pacific region 

Cytiva, a global life sciences leader, has successfully completed another KUBio 
installation, this time to global healthcare solutions provider Lonza, in 
Guangzhou Biopark, China.  The high throughput modular biomanufacturing 
facility will offer process development and manufacturing for Chinese companies 
developing innovative medicines, as well as multinationals with manufacturing 
requirements in China.

Photo -

Logo - 

The 17,000-square-meter site includes 6,500 square meters of lab space and one 
KUBio modular facility, and will enable quick ramp-up of antibody development 
services and manufacturing, which are urgently needed to respond to market 
needs for biologics, including mAbs and other complex proteins, in and for 
China, and the rest of the world.  

The Chinese biologics sector's growth has outpaced global growth, particularly 
in the last couple of years. According to estimates, the biologics market in 
China has surged from just under USD 10 billion in 2012 to over USD 45 billion 
in 2020.[1]

Stefan Stoffel, Chief Operating Officer, Lonza, says: "The Cytiva team showed 
great agility and speed in delivering this important site. With the KUBio and 
FlexFactory single-use platform now ready for business, Lonza will be able to 
respond to the great demand for innovative therapies in the current 
environment, now and in the future."

Olivier Loeillot, Vice President, Cytiva, says: "In a rapidly-growing industry 
with increasing needs for mAbs and other key biopharmaceuticals, this facility 
demonstrates the strength of combining modular manufacturing with single-use 
technologies.  Together, the KUBio and FlexFactory speed up delivery of 
innovative therapeutics to patients who need them."

At the Guangzhou Biopark site, construction and supplies of building materials 
were sometimes affected by lockdown and travel restrictions due to the COVID-19 
pandemic. Still, the overall project was completed within its expected time 

This is Lonza's first manufacturing site for biologics in China. Lonza will 
combine Cytiva's KUBio modular facility and single-use equipment to support its 
Good Manufacturing Practice (GMP) manufacturing integrated with its own 
platforms and expertise in development, including cell line construction and 
process development. Scaling up production will be streamlined when needed 
thanks to the flexibility in the design.

Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio, 
where Cytiva also provided solutions. Cytiva has delivered 77 KUBio and 
FlexFactory solutions to customers around the world.

For more information:
Read About KUBio ( 
Animation of Lonza site construction in Guangzhou ( 
Watch About the solution Cytiva provided for BeiGene ( 
Read the previous announcement with Lonza ( 

About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 
40 countries dedicated to advancing and accelerating therapeutics. As a trusted 
partner to customers that range in scale and scope, Cytiva brings speed, 
efficiency and capacity to research and manufacturing workflows, enabling the 
development, manufacture and delivery of transformative medicines to patients.

[1] Source:

SOURCE: Cytiva

CONTACT: In China, Iris Zhao, OR  In USA Colleen Connolly,